Back to Search
Start Over
Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population
- Source :
- Journal of pediatric hematology/oncology. 39(6)
- Publication Year :
- 2017
-
Abstract
- Pinarli, Faruk Guclu/0000-0002-3241-2478; Albayrak, Meryem/0000-0003-2711-5150 WOS: 000406231400018 PubMed: 28697165 Vincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated. Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols. Control group consisted of 50 children without any neurological symptom or disorders. All patient files were reviewed for presence and severeness of neurotoxicity symptoms. Blood samples were obtained and CYP3A5 genotypes were analyzed. Neurotoxicity occurred in 20.8% of patients. Although it was found to occur more frequently after 4 doses of vincristine, and rates were higher in the low-dose vincristine group suggesting other contributing factors. Although neurotoxicity rate in the CYP3A5*1/*3 genotype was 17.6%, it was 21.6% in the CYP3A5*3/*3 genotype and the difference was not statistically significant (P
- Subjects :
- medicine.medical_specialty
Neurotoxicity Syndrome
Turkish population
Vincristine
CYP3A5
Adolescent
Genotype
Turkey
medicine.medical_treatment
Pharmacology
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Internal medicine
Neoplasms
Medicine
genetic polymorphism
Cytochrome P-450 CYP3A
Humans
Adverse effect
Child
Chemotherapy
Dose-Response Relationship, Drug
business.industry
Case-control study
Neurotoxicity
Infant
Hematology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
medicine.disease
Antineoplastic Agents, Phytogenic
Oncology
030220 oncology & carcinogenesis
Case-Control Studies
Child, Preschool
Pediatrics, Perinatology and Child Health
Neurotoxicity Syndromes
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 15363678
- Volume :
- 39
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of pediatric hematology/oncology
- Accession number :
- edsair.doi.dedup.....a71569ab5c9c0318d79efe6c1174c3b6